Nivolumab
- PDF / 169,664 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 40 Downloads / 175 Views
1 S
Various toxicities: 6 case reports In a retrospective review of medical records involving 35 patients with post-operative recurrence of malignant pleural mesothelioma (MPM) treated with nivolumab between August 2018 and December 2019, six patients [ages and sexes not stated] were described, who developed autoimmune haemolytic anaemia (1 patient), mesenteric panniculitis (1 patient), proteinuria (1 patient), hyperthyroidism (1 patient), duodenal ulcer (1 patient) or herpes zoster (1 patient) during treatment with nivolumab for MPM. The patients underwent multimodality treatment, including curative-intent surgery for MPM. The patients received unspecified platinum-based doublet chemotherapy (neoadjuvant chemotherapy) prior to the curative-intent surgery. After the surgery, the patients were followed up for recurrence of MPM. After MPM recurrence, the patients were started on IV nivolumab 240mg, on day 1 of a 14-day cycle (every 2 weeks). Subsequently, the patients developed autoimmune haemolytic anaemia (n=1), mesenteric panniculitis (n=1), proteinuria (n=1), hyperthyroidism (n=1), duodenal ulcer (n=1) or herpes zoster (n=1) [durations of treatments to reactions onsets not stated]. The patients’ nivolumab was discontinued. In four of these patients, who developed proteinuria, hyperthyroidism, duodenal ulcer or herpes zoster, the nivolumab was restarted after the events abated [not all outcomes stated]. Nakamura A, et al. Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma. Japanese Journal of Clinical Oncology 50: 803519760 920-925, No. 8, Aug 2020
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
